On September 13, 2023 ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, reported that it will participate at the Jefferies Cell & Genetic Medicine Summit, to be held from September 26 -27, 2023 in New York, NY (Press release, ImmPACT-Bio, SEP 13, 2023, View Source;genetic-medicine-summit-301925364.html [SID1234635146]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio’s president and chief executive officer, will participate in a fireside chat on Wednesday, September 27, 2023 at 10:00 AM ET.

Management will also participate in one-on-one investor meetings. To schedule a one-on-one meeting please contact your Jefferies representative.